10:46 AM EST, 03/07/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ), (ARCH.V) on Thursday said that patient recruitment and dosing has begun in Turkey for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

There are three hospital sites in Turkey actively screening cardiac surgery patients for this trial. There are three additional hospital sites in Turkey pending activation into the trial.

The Arch Biopartners ( ACHFF ) team is currently working with hospital sites in Canada to prepare for their participation in this Phase II trial.

Price: 1.59, Change: +0.03, Percent Change: +1.92